Atlas Trials

Relapsing Forms of Multiple Sclerosis

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsing Forms of Multiple Sclerosis

RecordFirmDate
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) (NCT05083923)Biogen2021-11-18
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis (NCT04909502)Emerald Health Pharmaceuticals2021-10-19
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis (NCT04676555)Novartis Pharmaceuticals2021-05-11
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT02428218)Biogen2016-05-01
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (NCT02097849)Biogen2015-02-28
Plegridy Observational Program (NCT02230969)Biogen2014-11-12
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (NCT01903291)Biogen2013-08-01
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (NCT01873417)Biogen2013-05-01
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis (NCT01201356)Novartis Pharmaceuticals2010-09-13
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (NCT01216072)Novartis Pharmaceuticals2010-08-01
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) (NCT00424788)Biogen2007-01-01

Track Relapsing Forms of Multiple Sclerosis automatically

Every clearance here is in the API, with alerts when new ones post.